地诺单抗治疗骨质疏松症：预测10年以上的长期疗效 - Suppr

Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years.

作者信息

Lee Jeongmin, Lee Youn-Ju, Ha Jeonghoon

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.

出版信息

J Bone Metab. 2024 Aug;31(3):246-249. doi: 10.11005/jbm.2024.31.3.246. Epub 2024 Aug 31.

DOI:10.11005/jbm.2024.31.3.246

PMID:39307525

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11416879/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ff/11416879/20c1b5b32fd2/jbm-2024-31-3-246f1.jpg

相似文献

Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years.地诺单抗治疗骨质疏松症：预测10年以上的长期疗效

J Bone Metab. 2024 Aug;31(3):246-249. doi: 10.11005/jbm.2024.31.3.246. Epub 2024 Aug 31.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.在FREEDOM开放标签扩展研究中，长期使用地诺单抗治疗对非椎体骨折率的进一步降低作用以及3年后髋部骨密度的影响。

Osteoporos Int. 2015 Dec;26(12):2763-71. doi: 10.1007/s00198-015-3179-x. Epub 2015 Jun 12.

Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis.地舒单抗的长期持久性：来自奥地利骨质疏松症诊所（AOC）的真实世界数据。一项回顾性数据分析。

Osteoporos Int. 2022 Jan;33(1):263-272. doi: 10.1007/s00198-021-06102-2. Epub 2021 Aug 25.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.10 年地舒单抗治疗绝经后骨质疏松症妇女：来自 3 期随机 FREEDOM 试验和开放标签扩展的结果。

Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22.

Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials.地诺单抗治疗绝经后骨质疏松症女性的长期疗效评估：一项基于FRAX和虚拟孪生的事后分析，来自FREEDOM和FREEDOM扩展试验

JBMR Plus. 2020 Feb 24;4(4):e10348. doi: 10.1002/jbm4.10348. eCollection 2020 Apr.

Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.绝经后骨质疏松症女性中，通过组织厚度校正的骨小梁骨评分评估地舒单抗对骨微结构的长期影响：来自 FREEDOM 及其开放标签扩展的结果。

Osteoporos Int. 2023 Jun;34(6):1075-1084. doi: 10.1007/s00198-023-06708-8. Epub 2023 Mar 2.

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.在绝经后骨质疏松症妇女中，使用地舒单抗 5 年：自由延长研究头 2 年的结果。

J Bone Miner Res. 2012 Mar;27(3):694-701. doi: 10.1002/jbmr.1479.

Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.医疗保险按服务项目付费（FFS）覆盖的女性骨质疏松症治疗方式及长期药物维持治疗情况。

Osteoporos Int. 2021 Dec;32(12):2473-2484. doi: 10.1007/s00198-021-05951-1. Epub 2021 Jun 7.

When and how to stop denosumab therapy in a patient with osteoporosis.骨质疏松症患者何时以及如何停止地诺单抗治疗。

Clin Endocrinol (Oxf). 2023 May;98(5):649-653. doi: 10.1111/cen.14747. Epub 2022 May 9.

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).绝经后日本骨质疏松症女性和男性接受三年地诺单抗治疗：地诺单抗骨折干预随机安慰剂对照试验（DIRECT）1年开放标签扩展研究的结果

Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18.

引用本文的文献

Twenty-Year Trends in Osteoporosis Treatment and Post-Fracture Care in South Korea: A Nationwide Study.韩国骨质疏松症治疗与骨折后护理的二十年趋势：一项全国性研究。

J Bone Metab. 2025 Feb;32(1):57-66. doi: 10.11005/jbm.24.829. Epub 2025 Feb 28.

Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use.地诺单抗的长期疗效与安全性：超过10年使用经验的见解

Endocrinol Metab (Seoul). 2025 Feb;40(1):47-56. doi: 10.3803/EnM.2024.2125. Epub 2025 Jan 13.

本文引用的文献

Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea.立场声明：韩国绝经后骨质疏松症治疗策略

J Bone Metab. 2023 Nov;30(4):289-295. doi: 10.11005/jbm.2023.30.4.289. Epub 2023 Nov 30.

Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update.《台湾地区骨质疏松症防治临床实践指南：2022年更新版》

J Formos Med Assoc. 2023;122 Suppl 1:S4-S13. doi: 10.1016/j.jfma.2023.01.007. Epub 2023 Feb 11.

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.《成人原发性骨质疏松症或低骨量的药物治疗：美国医师学院临床实践指南》。

Ann Intern Med. 2023 Feb;176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3.

Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.真实世界中地舒单抗治疗骨质疏松症患者的安全性和有效性：韩国的一项前瞻性观察性研究。

Endocrinol Metab (Seoul). 2022 Jun;37(3):497-505. doi: 10.3803/EnM.2022.1427. Epub 2022 Jun 3.

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.停用地舒单抗：能否安全停药？文献复习。

Endocrinol Metab (Seoul). 2022 Apr;37(2):183-194. doi: 10.3803/EnM.2021.1369. Epub 2022 Apr 14.

UK clinical guideline for the prevention and treatment of osteoporosis.英国临床骨质疏松症预防和治疗指南。

Arch Osteoporos. 2022 Apr 5;17(1):58. doi: 10.1007/s11657-022-01061-5.

Predictive factors for achievement of treatment goals in patients with postmenopausal osteoporosis treated with denosumab.地舒单抗治疗绝经后骨质疏松症患者治疗目标达成的预测因素。

Mod Rheumatol. 2023 Jan 3;33(1):217-223. doi: 10.1093/mr/roab129.

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.地舒单抗治疗骨质疏松症：10 年后：叙事性综述。

Adv Ther. 2022 Jan;39(1):58-74. doi: 10.1007/s12325-021-01936-y. Epub 2021 Nov 11.

Long-Term Treatment of Postmenopausal Osteoporosis.绝经后骨质疏松症的长期治疗。

Endocrinol Metab (Seoul). 2021 Jun;36(3):544-552. doi: 10.3803/EnM.2021.301. Epub 2021 Jun 22.

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.地诺单抗治疗中断的骨折风险与管理：欧洲钙化组织协会的系统评价与立场声明

J Clin Endocrinol Metab. 2020 Oct 26. doi: 10.1210/clinem/dgaa756.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献